SITC Resource Library

On August 25, 2021, leading experts in cancer immunotherapy presented an overview of the publication "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer" during a live webinar. The recorded webinar and presentation slides are available below.

Webinar Faculty:

• Moderator: Ashish M. Kamat, MD, MBBS, FACS – The University of Texas MD Anderson Cancer Center (Expert Panel Chair)
• Peter C. Black, MD – University of British Columbia (Expert Panel Member)
  
• Matthew D. Galsky, MD– Tisch Cancer Institute at Mount Sinai Medical Center (Expert Panel Chair)
• Arjun V. Balar, MD – Perlmutter Cancer Center - NYU Langone Medical (Expert Panel Member)

• SITC's Cancer Immunotherapy Guideline on the treatment of urothelial cancer
  
• The use of biomarkers to predict patient response during different stages of treatment
  
• Bacillus Calmette-Guerin as the standard of care for non-muscle invasive bladder cancer and alternatives for non-responsive patients
  
• First- and second-line treatments and management for advanced urothelial cancer
• Future directions in the field of urothelial cancer immunotherapies
  

Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, please visit connected.sitcancer.org.